PLOD1 and neoplasm: Degarelix has been associated with lower LH and FSH levels than leuprolide, suggesting a more complete shutdown of testicular steroidogenesis (Gittleman et al., 2008), and hence, a better tumor response (Klotz et al., 2008; Crawford et al., 2011).